Cargando…
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio...
Autores principales: | Amanat, Fatima, Thapa, Mahima, Lei, Tinting, Sayed Ahmed, Shaza M., Adelsberg, Daniel C., Carreno, Juan Manuel, Strohmeier, Shirin, Schmitz, Aaron J., Zafar, Sarah, Zhou, Julian Q, Rijnink, Willemijn, Alshammary, Hala, Borcherding, Nicholas, Reiche, Ana Gonzalez, Srivastava, Komal, Sordillo, Emilia Mia, van Bakel, Harm, Turner, Jackson S., Bajic, Goran, Simon, Viviana, Ellebedy, Ali H., Krammer, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987037/ https://www.ncbi.nlm.nih.gov/pubmed/33758878 http://dx.doi.org/10.1101/2021.03.07.21253098 |
Ejemplares similares
-
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
por: Amanat, Fatima, et al.
Publicado: (2021) -
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
por: Carreño, Juan Manuel, et al.
Publicado: (2021) -
Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain
por: Altomare, Clara G., et al.
Publicado: (2022) -
tRNA abundance, modification and fragmentation in nasopharyngeal swabs as biomarkers for COVID-19 severity
por: Katanski, Christopher D., et al.
Publicado: (2022) -
Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD
por: Peter, Antonia Sophia, et al.
Publicado: (2022)